		Type: Drug Guideline	Document reference: 2955	Manual Classification: Waikato DHB Drug Guidelines
Title: Potassium chloride for neonates			Effective date: 01 September 2018	
Facilitator <small>sign/date</small>	Authorised <small>sign/date</small>	Authorised <small>sign/date</small>	Version: 01	Page: 1 of 4
<i>Jessica Yule</i> Pharmacist	<i>David Bouchier</i> Clinical Director NICU	<i>John Barnard</i> Chair Medicines & Therapeutics	Document expiry date: 01 September 2021	

© Waikato DHB, September 2018

BRIEF ADMINISTRATION GUIDE

(For more detailed guideline information please see the following pages)

Indications:

- Treatment of hypokalaemia^{1,2}
- Daily maintenance^{2,3}

Route:

Intravenous or oral¹⁻⁵

Dose:

Treatment of hypokalaemia

- 0.5 – 1 mmol/kg/dose administered via intravenous infusion¹⁻³
- Dose may be repeated if required based on serum potassium level¹⁻³

Daily maintenance

- 2 – 4 mmol/kg/day^{2,3,6}. Doses up to 6 mmol/kg/day may be required for severe depletion¹
- Daily dose can be given orally in divided doses every 6 hours with feeds, or by intravenous infusion^{3,7}
- Adjust dosage based on monitoring of serum potassium levels³

Supplied as:


- Potassium chloride 1 mmol/ml, 10 ml injection⁴
- Potassium chloride 2 mmol/ml oral liquid, 25 ml⁵

Preparation and administration:

- Potassium must be diluted prior to parenteral administration¹
- Solution must be diluted to a maximum concentration of 1 mmol/25 ml (40 mmol/L) for a peripheral line^{1-3,6,8}
- Solution must be diluted to a maximum concentration of 1 mmol/12.5 ml (80 mmol/L) for a central line^{1,3,6,7}
- When adding potassium chloride to an IV fluid bag, mix well by inverting the bag at least 10 times. Do not add potassium chloride to a bag that is already hanging⁹
- Infuse at a rate not exceeding 0.2 mmol/kg/h^{6,9}

Monitoring:

- Monitor serum potassium regularly with frequency determined by clinical situation^{1,3}
- Monitor renal function, electrolytes, urine output at baseline and periodically throughout treatment^{1,10}
- Continuous cardiac monitoring for intravenous infusion^{1-3,10}
- Monitor blood pressure, heart rate, respiratory rate and temperature periodically during treatment²
- Monitor injection site for irritation, extravasation³
Assess for signs of anaphylaxis or adverse reactions

	Document reference: 2955	Effective date: 01 Sep 2018	Expiry date: 01 Sep 2021	Page: 2 of 4
	Title: Potassium chloride for neonates	Type: Drug Guideline	Version: 01	Authorising initials:

1. Purpose and scope


To facilitate the safe and effective use of potassium chloride in the neonatal intensive care unit (NICU).

Note:

Potassium is a ISMP high alert medication that has an increased risk of causing significant harm if used in error^{1,2}. Extreme caution is necessary when administering potassium chloride as overdose or rapid administration can cause cardiac arrest⁹.

2. Drug


Drug	Potassium chloride
Drug action	<p>Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in the heart, brain and skeletal muscle, contractions of cardiac, skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism and gastric secretion^{1,10}.</p> <p>Serum potassium levels can be a poor marker of total body stores of potassium, and a low serum potassium level in the neonatal period more often reflects redistribution than true deficit^{6,8}.</p>
Indications	<ul style="list-style-type: none"> • Treatment of hypokalaemia^{1,2} • Daily maintenance^{2,3}
Presentation	<ul style="list-style-type: none"> • Potassium chloride 1 mmol/ml, 10 ml injection⁴. Clear colourless solution¹¹. Excipients include water for injection¹⁰ • Potassium chloride 2 mmol/ml oral liquid, 25 ml⁵.
Route	Intravenous or oral ¹⁻⁵
Dose	<p>Treatment of hypokalaemia</p> <ul style="list-style-type: none"> • 0.5 – 1 mmol/kg/dose administered via intravenous infusion¹⁻³ • Dose may be repeated if required based on serum potassium levels¹⁻³ <p>Daily maintenance</p> <ul style="list-style-type: none"> • 2 – 4 mmol/kg/day^{2-3,6}. Doses up to 6 mmol/kg/day may be required for severe depletion¹ • Daily dose can be given orally in divided doses every 6 hours with feeds, or by intravenous infusion^{3,7} • Adjust dosage based on monitoring of serum potassium levels³
Contraindications	<ul style="list-style-type: none"> • Hypersensitivity to potassium or any component of the preparation¹ • Hyperkalaemia^{1,4,5,10} • Severe renal impairment^{1-3,10} • Untreated Addison's disease^{1,10} • Severe tissue trauma^{1,10}
Precautions	<ul style="list-style-type: none"> • Cardiac disease and/or renal disease^{1,2,10} • Concurrent use of drugs which increase the risk of hyperkalaemia e.g. potassium sparing diuretics^{1,2}, ACE inhibitors, NSAIDs, cyclosporine, tacrolimus, digoxin^{6,7,10} • Acute acidosis or alkalosis^{5,10} • Sickle cell disease^{2,10}

	Document reference: 2955	Effective date: 01 Sep 2018	Expiry date: 01 Sep 2021	Page: 3 of 4
	Title: Potassium chloride for neonates		Type: Drug Guideline	Version: 01

Incompatibilities	<ul style="list-style-type: none"> Compatible with sodium chloride 0.9%, glucose 5%, glucose 10%, Lactated Ringer's (Hartmann's), glucose and sodium chloride combinations^{9,11} Avoid glucose during initial replacement – may cause transient hypokalaemia¹¹ Incompatible with amikacin, amphotericin B, amoxicillin, benzylpenicillin, diazepam, dobutamine, mannitol, methylprednisolone, phenytoin, promethazine^{3,10,11}
Adverse effects	<ul style="list-style-type: none"> Hyperkalaemia¹ Cardiac arrhythmias (heart block, peaked T waves), hypotension^{3,10} Abdominal pain, diarrhoea, flatulence, nausea, vomiting^{1,5,10} Gastrointestinal bleeding, obstruction, or perforation with oral use (may be reduced by administering with feeds)¹ Signs of potassium toxicity include paraesthesia of the extremities, weakness, mental confusion^{3,10} Injection site reactions including thrombophlebitis, pain and tissue necrosis due to extravasation^{2,3,8,10}

3. Administration

Competency for administration	This procedure is carried out by, or under, the direct supervision of a registered nurse/registered midwife who holds current Waikato DHB Generic Medicine Management and IV certification as well as Neonatal specific competency NCV/NAC.
Preparation & Administration	<ul style="list-style-type: none"> Potassium must be diluted prior to parenteral administration¹ Solution must be diluted to a maximum concentration of 1 mmol/25 ml (40 mmol/L) for a peripheral line^{1-3,6,8} Solution must be diluted to a maximum concentration of 1 mmol/12.5 ml (80 mmol/L) for a central line^{1,3,6,8} When adding potassium chloride to an IV fluid bag, mix well by inverting the bag at least 10 times. Do not add potassium chloride to a bag that is already hanging⁹ Clearly label all bags, syringes, pumps and lines that contain potassium to avoid inadvertent flushing⁹ Infuse at a rate not exceeding 0.2 mmol/kg/h^{6,9}
Observations and management	<ul style="list-style-type: none"> Monitor serum potassium regularly with frequency determined by clinical situation^{1,3} Monitor renal function, electrolytes, urine output at baseline and periodically throughout treatment^{1,10} Continuous cardiac monitoring for intravenous infusion^{1-3,10} Monitor blood pressure, heart rate, respiratory rate and temperature periodically during treatment² Monitor injection site for irritation, extravasation³ Assess for signs of anaphylaxis or adverse reactions
Special considerations (audit, funding, storage)	<ul style="list-style-type: none"> Potassium chloride injection has a pH of 4 to 8¹¹ Potassium ampoules and oral solution should be stored at room temperature below 25 °C¹¹ Diluted potassium chloride solutions should be prepared immediately before use, but is stable if refrigerated between 2 to 8 °C for up to 24 hours¹¹ Discard any unused solution

	Document reference: 2955	Effective date: 01 Sep 2018	Expiry date: 01 Sep 2021	Page: 4 of 4
	Title: Potassium chloride for neonates	Type: Drug Guideline	Version: 01	Authorising initials:

Rescue medication	Discontinue immediately and seek urgent medical assistance if anaphylaxis or severe adverse reactions occur. Administer adrenaline and maintain airway as appropriate.
--------------------------	--

4. Guardrails

Potassium Chloride is not Guardrails profiled for NICU.

5. References

1. American Pharmacists Association. Pediatric & Neonatal Dosage Handbook. 20th edition. 2013.
2. Phelps SJ, Hagemann TM, Lee KR, Thompson AJ. The Teddy Bear Book: Pediatric Injectable Drugs. 10th edition. Sodium Bicarbonate. American Society of Health-System Pharmacists; 2013.
3. Truven Health Analytics Inc. Pediatrics and Neofax®. 2018. Potassium monograph. Accessed 21st May 2018. Available from: <http://www.micromedexsolutions.com>.
4. New Zealand Formulary for Children (NZFC). 2018. Potassium chloride (intravenous). Accessed 21st May 2018. Available from: http://www.nzfchildren.org.nz/nzf_5057.
5. New Zealand Formulary for Children (NZFC). 2018. Potassium salts (oral). Accessed 21st May 2018. Available from: http://www.nzfchildren.org.nz/nzf_5021.
6. Auckland DHB Newborn Services. Potassium Chloride Drug Protocol. April 2012. Available from: <http://www.adhb.govt.nz/newborn/DrugProtocols>
7. Canterbury DHB Neonatal Services. Potassium Chloride Drug Information Sheet. March 2016. Available from: <http://www.cdhb.health.nz/Hospitals-Services/Health-Professionals/Neonatal-Clinical-Resources/Neonatal-Drug-Information-Sheets>.
8. Ainsworth SB. Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life 7th ed. John Wiley & Sons Incorporated; 2014.
9. The Royal Children's Hospital Melbourne. Paediatric Injectable Guidelines. Accessed 21st May 2018. Available from: <https://pig.rch.org.au>.
10. Astra Zeneca Ltd. Potassium Chloride Data Sheet. 13 October 2017. Available from: <http://www.medsafe.govt.nz/profs/datasheet/p/PotassiumChlorideInj.pdf>
11. New Zealand Hospital Pharmacists Assoc. Inc. Notes on Injectable Drugs 7th ed, 2015.

Disclaimer: This document has been developed by Waikato District Health Board specifically for its own use. Use of this document and any reliance on the information contained therein by any third part is at their own risk and Waikato District Health Board assumes no responsibility whatsoever.